Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s): N.MMED.WA | N.MMED.WR | N.MMED.WS | N.MMED

Healthcare

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc

Bullboard Posts

Comment by josameyeron Sep 27, 2010 9:59am

359 Views

Post# 17495507

RE: Q3 NEWS

Brigus continues to ramp up production. We had a 24 hour shutdown to replace a motor on the primary ballmill. The mill throughput was still over 1950 tonnes per day. Since the replacement of the motor, we are running at 2000 tonnes per day at an average grade of 3.9 gr per tonne. this is in reference to the third quarter.The construction workforce to be displaced by mid 2011. Average cost of production is from 500 to 550 dollars per ounce..Good news in my opinion DYODD. Cheers to all.

Bullboard Posts

Level up your trading with BMO InvestorLine’s enhanced features